Ractigen Therapeutics Co. Ltd.’s small activating RNA (saRNA) therapeutic, RAG-18, has been awarded U.S. orphan drug designation for the treatment of Duchenne muscular dystrophy (DMD) and Becker ...
– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date – – On ...
– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., ...
The drug tadalafil (Cialis, Lilly), already approved to treat erectile dysfunction and pulmonary hypertension, also corrects abnormal blood flow in exercised forearms of men with Becker muscular ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
Discover the various types, causes, symptoms, diagnosis, and treatments for muscular dystrophy, along with early warning signs and effective care strategies ...
U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the August 31, ...
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback